The globally watched case related to an Indian pharma company's request to the country's patent office for a compulsory license to make a generic version of Bayer's patented drug to treat liver and kidney cancer has been settled on March 13, 2012. In a first-of-its-kind ruling in one of the world's fastest growing pharma markets,… Continue reading India Allows Compulsory Licensing Of Bayer’s Anti-Cancer Drug Sorafenib To NATCO Pharma